How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

Microsoft’s Copilot generative AI is popping up on the web, in mobile apps, in the Edge browser, and especially in Windows. But just what exactly is it? Here’s everything you need to know. I've been ...

The biotech entered 2025 with around 800 employees. (iStock / Getty Images Plus) Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful ...

Recursion Pharmaceuticals on Tuesday said results from a mid-stage trial showed its lead experimental drug to be safe, the first readout in a series of important data disclosures for the AI drug ...